Literature DB >> 27830020

Evaluation of a research use only luminex based assay for measurement of procalcitonin in serum samples.

Charles Garrigan1, Jennifer Han2, Pam Tolomeo3, Katherine J Johnson4, Stephen R Master5, Ebbing Lautenbach2, Irving Nachamkin1.   

Abstract

Research use only (RUO) assays do not undergo a validation process similar to test kits used for clinical purposes. Several studies have suggested that RUO assays need to be validated prior to use in any research studies. We evaluated a research use only Luminex platform based assay for measuring serum procalcitonin levels (Bio-Plex ProTM Human Acute Phase Multiplex Assay, Bio-Rad Laboratories, Hercules, CA) for comparability with an FDA cleared assay for procalcitonin (VIDAS B.R.A.H.M.S. PCT Assay, bioMérieux, Durham, NC). We tested 1,072 serum samples collected from patients with suspected sepsis in an intensive care unit setting for the comparison. There was poor correlation of the luminex based assay (r=0.081) with the VIDAS PCT Assay in the clinically relevant measurement range (<10 ng/mL). Additionally the Bio-Plex assay showed poor precision. Mass-spectrometry analysis of material eluted from PCT beads did not reveal any identifiable procalcitonin. The results show that research use only assays need to be validated to determine their suitability for research studies.

Entities:  

Keywords:  Biomarkers; luminex; procalcitonin; research use only (RUO) assays; sepsis

Year:  2016        PMID: 27830020      PMCID: PMC5095329     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  14 in total

1.  PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry.

Authors:  Bin Ma; Kaizhong Zhang; Christopher Hendrie; Chengzhi Liang; Ming Li; Amanda Doherty-Kirby; Gilles Lajoie
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

2.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller
Journal:  Am J Respir Crit Care Med       Date:  2006-04-07       Impact factor: 21.405

3.  False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

Authors:  Ioannis Prassas; Davor Brinc; Sofia Farkona; Felix Leung; Apostolos Dimitromanolakis; Caitlin C Chrystoja; Randall Brand; Vathany Kulasingam; Ivan M Blasutig; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2013-10-04       Impact factor: 8.327

4.  As if biomarker discovery isn't hard enough: the consequences of poorly characterized reagents.

Authors:  Karin D Rodland
Journal:  Clin Chem       Date:  2013-12-04       Impact factor: 8.327

5.  Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans.

Authors:  Orlando M Gutiérrez; Chia Chi Sun; Wenjie Chen; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Nephrol       Date:  2012-09-22       Impact factor: 3.754

6.  Commercial immunoassays in biomarkers studies: researchers beware!

Authors:  Nader Rifai; Ian D Watson; W Greg Miller
Journal:  Clin Chem       Date:  2012-07-12       Impact factor: 8.327

7.  Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients.

Authors:  A Aouifi; V Piriou; O Bastien; P Blanc; H Bouvier; R Evans; M Célard; F Vandenesch; R Rousson; J J Lehot
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

8.  Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children.

Authors:  A Enguix; C Rey; A Concha; A Medina; D Coto; M A Diéguez
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

9.  Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department.

Authors:  Martijn D de Kruif; Maarten Limper; Herman Gerritsen; C Arnold Spek; Dees P M Brandjes; Hugo ten Cate; Patrick M Bossuyt; Pieter H Reitsma; Eric C M van Gorp
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

10.  Use of a Combination Biomarker Algorithm To Identify Medical Intensive Care Unit Patients with Suspected Sepsis at Very Low Likelihood of Bacterial Infection.

Authors:  Jennifer H Han; Irving Nachamkin; Susan E Coffin; Jeffrey S Gerber; Barry Fuchs; Charles Garrigan; Xiaoyan Han; Warren B Bilker; Jacqueleen Wise; Pam Tolomeo; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

View more
  1 in total

1.  A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19.

Authors:  Jinwei Du; Eric Chu; Dayu Zhang; Chuanyi M Lu; Aiguo Zhang; Michael Y Sha
Journal:  J Virol Methods       Date:  2020-11-02       Impact factor: 2.014

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.